PRTK Stock - Paratek Pharmaceuticals, Inc.
Unlock GoAI Insights for PRTK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $150.79M | $120.95M | $43.52M | $16.54M | $17.12M |
| Gross Profit | $127.73M | $99.42M | $34.87M | $13.06M | $17.12M |
| Gross Margin | 84.7% | 82.2% | 80.1% | 78.9% | 100.0% |
| Operating Income | $-46,209,000 | $-41,130,000 | $-75,504,000 | $-115,629,000 | $-104,085,000 |
| Net Income | $-63,566,000 | $-59,084,000 | $-116,259,000 | $-128,790,000 | $-112,356,000 |
| Net Margin | -42.2% | -48.8% | -267.2% | -778.5% | -656.4% |
| EPS | $-1.17 | $-1.22 | $-2.63 | $-3.93 | $-3.57 |
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 2nd 2023 | Jefferies | Resumed | Buy | $5← $7 |
| April 17th 2023 | BTIG Research | Resumed | Buy | $24 |
Earnings History & Surprises
PRTKEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 1, 2024 | — | — | — | — |
Q2 2024 | May 7, 2024 | — | — | — | — |
Q1 2024 | Mar 14, 2024 | — | — | — | — |
Q4 2023 | Nov 2, 2023 | $-0.25 | $-0.38 | -52.0% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $0.31 | $0.25 | -19.4% | ✗ MISS |
Q2 2023 | May 9, 2023 | $0.38 | $0.35 | -7.9% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $0.04 | $0.12 | +228.6% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $0.27 | $0.38 | +40.7% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $0.35 | $0.33 | -5.7% | ✗ MISS |
Q2 2022 | May 4, 2022 | $0.35 | $0.35 | 0.0% | = MET |
Q1 2022 | Mar 14, 2022 | $-0.41 | $0.64 | +256.1% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $0.48 | $0.37 | -22.9% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $0.32 | $0.20 | -37.5% | ✗ MISS |
Q2 2021 | May 17, 2021 | $0.22 | $0.39 | +77.3% | ✓ BEAT |
Q1 2021 | Feb 24, 2021 | $0.08 | $0.49 | +512.5% | ✓ BEAT |
Q4 2020 | Nov 5, 2020 | $0.61 | $0.46 | -24.6% | ✗ MISS |
Q3 2020 | Aug 10, 2020 | $0.14 | $0.53 | +278.6% | ✓ BEAT |
Q2 2020 | May 11, 2020 | $0.83 | $0.66 | -20.5% | ✗ MISS |
Q1 2020 | Feb 25, 2020 | $1.03 | $0.81 | -21.4% | ✗ MISS |
Q4 2019 | Nov 12, 2019 | $1.06 | $1.00 | -5.7% | ✗ MISS |
Latest News
Frequently Asked Questions about PRTK
What is PRTK's current stock price?
What is the analyst price target for PRTK?
What sector is Paratek Pharmaceuticals, Inc. in?
What is PRTK's market cap?
Does PRTK pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PRTK for comparison